Dawnrays Pharmaceutical (Holdings) (SEHK:2348) - Aktienkurs, Nachrichten und Analyse

2348 Aktienübersicht

2348 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	5/6
Dividenden	4/6

Belohnungen

Das Kurs-Gewinn-Verhältnis (5x) liegt unter dem Hong Kong Markt (9.5x)

Risikoanalyse

Unbeständige Dividendenentwicklung

Dawnrays Pharmaceutical (Holdings) Limited Wettbewerber

Jacobson Pharma

SEHK:2633

HK$1.3b

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$1.1b

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$733.9m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Dawnrays Pharmaceutical (Holdings)
Historische Aktienkurse
Aktueller Aktienkurs	HK$1.21
52-Wochen-Hoch	HK$1.35
52-Wochen-Tief	HK$0.98
Beta	0.73
11 Monat Veränderung	4.31%
3 Monate Veränderung	3.42%
1 Jahr Veränderung	0.83%
33 Jahre Veränderung	-32.78%
5 Jahre Veränderung	-17.12%
Veränderung seit IPO	191.57%

Aktuelle Nachrichten und Updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

May 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Apr 22

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

May 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Apr 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23

Aktionärsrenditen

	2348	HK Pharmaceuticals	HK Markt
7D	2.5%	-1.7%	-1.0%
1Y	0.8%	-7.7%	0.7%

Rendite im Vergleich zur Industrie: 2348 übertraf die Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -3.5 erzielte.

Rendite vs. Markt: 2348 entspricht dem Hong Kong Markt, der im vergangenen Jahr eine Rendite von 1.3 erzielte.

Preisvolatilität

Is 2348's price volatile compared to industry and market?
2348 volatility
2348 Average Weekly Movement	2.9%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 2348 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 2348Die wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1995	1,143	Weixian Wu	www.dawnrays.com

Dawnrays Pharmaceutical (Holdings) Limited, eine Investment-Holdinggesellschaft, entwickelt, produziert und verkauft nicht patentgeschützte pharmazeutische Arzneimittel in Festlandchina und international. Das Unternehmen ist in zwei Segmenten tätig: Zwischenprodukte und Bulk-Medikamente sowie Fertigarzneimittel. Das Unternehmen bietet Antibiotika an, darunter pharmazeutische Zwischenprodukte, Bulk-Medikamente, Pulver für Injektionen und orale Antibiotika.

Dawnrays Pharmaceutical (Holdings) Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Dawnrays Pharmaceutical (Holdings) im Vergleich zum Marktanteil des Unternehmens?
2348 grundlegende Statistiken
Marktanteil	HK$1.82b
Gewinn(TTM)	HK$350.30m
Umsatz(TTM)	HK$1.24b

5.2x

Kurs-Gewinn-Verhältnis

1.5x

Kurs-Umsatz-Verhältnis

Ist 2348 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
2348 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CN¥1.15b
Kosten der Einnahmen	CN¥522.67m
Bruttogewinn	CN¥628.48m
Sonstige Ausgaben	CN¥302.48m
Umsatz	CN¥326.00m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.22
Bruttomarge	54.60%
Nettogewinnspanne	28.32%
Schulden/Eigenkapital-Verhältnis	4.2%

Wie hat sich 2348 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

6.6%

Aktuelle Dividendenrendite

33%

Ausschüttungsquote

2348 Aktienübersicht

Belohnungen

Risikoanalyse

Dawnrays Pharmaceutical (Holdings) Limited Wettbewerber

SEHK:2633

HK$1.3b

SEHK:3737

HK$1.1b

SEHK:503

HK$750.6m

SEHK:8049

HK$733.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.065 per share

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.065 per share

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 24, 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Final dividend of HK$0.065 announced

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.24 in FY 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Upcoming dividend of HK$0.015 per share at 7.1% yield

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

First half 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 1H 2022)

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2024 Results on Aug 25, 2023

Dawnrays Pharmaceutical (Holdings) Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.073 per share at 6.2% yield

Chief Executive Officer recently bought HK$2.6m worth of stock

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Full year 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in FY 2021)

Insufficient new directors

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings) Limited(SEHK:2348) dropped from S&P Global BMI Index

Upcoming dividend of HK$0.015 per share

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.11 in 1H 2021)

Dawnrays Pharmaceutical (Holdings) Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022

Dawnrays Pharmaceutical (Holdings) Limited to Report First Half, 2022 Results on Aug 26, 2022

Dawnrays Pharmaceutical (Holdings) Limited Declares Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.065 per share

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Dawnrays Pharmaceutical (Holdings) Limited, Annual General Meeting, May 27, 2022

Dawnrays Pharmaceutical (Holdings) Ltd Ordinary Shares Deleted from Other OTC

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Dawnrays Pharmaceutical (Holdings) Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Dawnrays Pharmaceutical (Holdings) Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings) Limited Announces Initiation of Phase III Clinical Trial for Primary Hypercholesterolemia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 1H 2020)

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

CEO & Executive Director recently bought HK$349k worth of stock

Dawnrays Pharmaceutical (Holdings) Limited Approves Special Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.10 per share

Investor sentiment improved over the past week

Co-Founder & Executive Director recently bought HK$573k worth of stock

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.16 in FY 2019)

Dawnrays Pharmaceutical (Holdings) Limited Recommends Special Dividend for the Year Ended 31 December 2020

Co-Founder & Executive Chairman recently bought HK$425k worth of stock

Co-Founder & Executive Chairman recently bought HK$231k worth of stock

Full year 2020 earnings released

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Erträge & Einnahmen